# Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

> **NCT00641056** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 467 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Exenatide Once Weekly
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT00641056
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-05
- **Final completion:** 2009-11
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2015-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00641056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00641056, "Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00641056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*